Y-Intercept (HK)’s Rigel Pharmaceuticals RIGL Stock Holding History

Y-Intercept (HK)’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,803	Closed	-$779K	–	2090
2026 Q1	$779K	Buy	28,803 +546	+2%	+$18.3K	0.01%	1118
2025 Q4	$1.21M	Buy	28,257 +4,440	+19%	+$167K	0.03%	892
2025 Q3	$675K	Buy	+23,817	New	+$712K	0.02%	1151
2022 Q4	–	Sell	-18,678	Closed	-$220K	–	1294
2022 Q3	$220K	Buy	+18,678	New	+$253K	0.02%	794

Other funds holding RIGL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s RIGL Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Rigel Pharmaceuticals (RIGL) in Q2 2026, closing a stake of 28,803 shares — an estimated $779K sold.

Y-Intercept (HK) first reported a position in RIGL in Q3 2022 and held it in 4 quarters. The position peaked at $1.21M in Q4 2025. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

Y-Intercept (HK) reported no remaining Rigel Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 28,803 Rigel Pharmaceuticals shares in Q2 2026, an estimated $779K.
Y-Intercept (HK) first reported a position in Rigel Pharmaceuticals in Q3 2022 and held it in 4 quarters.
Y-Intercept (HK)'s Rigel Pharmaceuticals position peaked at $1.21M in Q4 2025.
156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.